Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study.

ABSTRACT:

Background

Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this applies to severely obese patients needs to be determined.

Objective

To compare the effectiveness and safety of dabigatran with warfarin among AF patients with severe obesity.

Design

Retrospective cohort study.

Participants

AF patients with a BMI >40kg/m² or a weight >120kg receiving dabigatran or warfarin between 10/01/2010 and 12/31/2019 in a large integrated health system and followed through 08/01/2020.

Interventions

Not applicable.

Main measures

Primary effectiveness outcome was composite thromboembolism including transient ischemic attack, ischemi

SUBMITTER: Huang CW 

PROVIDER: S-EPMC9485368 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature